Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EED | O75530 | 2/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | MC4R | P32245 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | MC5R | P33032 | 2/20 | 0.31 |
| ▸ | MC1R | Q01726 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4779421 | 0.93 | MCHR1 (0.34) | EEDMCHR1MC4RALDH1A1GAA | |
| SCHEMBL4779404 | 0.93 | MCHR1 (0.34) | EEDMCHR1MC4RALDH1A1GAA | |
| SCHEMBL4019099 | 0.91 | ALDH1A1 (0.35) | EEDMCHR1ALDH1A1GAAMEN1 | |
| SCHEMBL4023939 | 0.89 | MCHR1 (0.37) | MCHR1ALDH1A1GAAMEN1KMT2A | |
| SCHEMBL4025011 | 0.86 | MCHR1 (0.30) | MCHR1 | |
| SCHEMBL4026452 | 0.86 | ALDH1A1 (0.40) | MCHR1ALDH1A1GAAMEN1KMT2A | |
| SCHEMBL4028159 | 0.80 | ALDH1A1 (0.39) | MCHR1ALDH1A1GAAMEN1KMT2A | |
| SCHEMBL4779411 | 0.79 | MC4R (0.34) | MCHR1MC4RALDH1A1GAAMEN1 | |
| SCHEMBL4021692 | 0.76 | ALDH1A1 (0.38) | ALDH1A1GAAMEN1KMT2ALMNA | |
| SCHEMBL4022338 | 0.76 | MEN1 (0.32) | EEDNTRK1MC4RMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | disclosed |
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | TP53, VHL, RB1 | EED 1022/4885NTRK1 3738/4885MCHR1 3670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.